MicroPort’s Endovastec unit said the FDA granted Breakthrough Device Designation to its investigational Hector Multi-Branch Thoracic Stent Graft System for endovascular treatment of complex aortic arch disease. The device is designed to support reconstruction of the aortic arch and all three supra-aortic branches. Endovastec also said Hector was admitted to China’s Green Channel for Innovative Medical Devices for prioritized regulatory review.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief on March 13, 2026, and is solely responsible for the information contained therein.
Comments